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Implication for health policy/practice/research/medical education:
The aim of this study was to investigate DGF risk factors and determine the association of intraoperative rATG with the risk 
of DGF in deceased donor kidney recipients at our centers. This study showed that intraoperative rATG induction therapy was 
associated with decreased incidence of DGF in deceased donor kidney recipients. In addition, intraoperative blood transfusion 
and recipient diabetes were independent risk factors for DGF.
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Introduction: Delayed graft function (DGF) is associated with significant adverse outcomes 
in deceased donor kidney transplantation (KT) including lower graft survival. However, risk 
factors and potential preventive strategies like intraoperative rabbit antithymocyte globulin 
(rATG; thymoglobulin) have not yet been fully evaluated.
Objectives: The aim of this study was to investigate DGF risk factors and determine the 
association of intraoperative rATG with the risk of DGF in deceased donor kidney recipients.
Patients and Methods: We retrospectively examined medical records of 163 first time 
deceased donor kidney transplant recipients at two major kidney transplant centers from 2014 
to 2016. All the donors were standard heart-beating, brain death donors. Risk factors for DGF 
in recipients were evaluated using multivariate logistic regression analysis.
Results: The mean recipients’ age was 43±13 years and the majority of participants were male 
(64%). The overall rate of DGF was 27%. Intraoperative rATG was significantly associated 
with a lower rate of DGF (adjusted odds ratio [AOR], 0.33, 95% CI, 0.11-0.95). Intraoperative 
transfusion (AOR, 3.7, 95% CI, 1.4-9.9) and diabetes mellitus (AOR, 3.7, 95% CI, 1.5-8.9) were 
significantly associated with higher risk of DGF.
Conclusion: This study showed that intraoperative blood transfusion and diabetes mellitus 
were associated with increased risk of DGF. Meanwhile, administration of intraoperative 
rATG was associated with reduced odds ratio of DGF. Future studies are needed to evaluate 
the potential role of rATG in DGF-related renal outcomes.
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In patients with end-stage renal disease (ESRD), kidney 
transplantation (KT) is the most desired modality for 
renal replacement therapy (1) given that it improves 
quality of life and is associated with a lower risk of 
mortality compared to maintenance dialysis (2). However, 
KT is not without risks as renal allograft recipients may 
encounter various post-transplant complications such as 
rejection or delayed graft function (DGF), both of which 
can adversely impact graft and patient survival. DGF, 
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usually defined as the need for dialysis within seven days 
following transplantation, is a well-known complication 
especially in deceased donor kidney recipients. While 
DGF has a lower incidence in living donor kidney 
recipients (3), its frequency in deceased donor kidney 
recipients varies widely from 5% to 50% (4, 5) due to 
several factors including differences in DGF definitions, 
administered induction immunosuppressive regimens, 
organ procurement techniques and many other factors 
that might affect the risks and incidence rate of DGF 
in different transplant centers (4). Other well-studied 
recipient related risk factors for DGF include male gender, 
high body mass index (BMI), previous transplant, diabetes, 
pre-transplant dialysis and its duration and need for pre-
transplant transfusion (6). Regardless of underlying cause, 
DGF occurrence is associated with shorter graft survivals 
and higher acute cellular rejection episodes (6).
Rabbit antithymocyte globulin (rATG; thymoglobulin) 
is frequently used as an induction therapy agent in 
deceased donor KT especially in recipients with increased 
immunologic risk factors in order to reduce the risk of graft 
rejection and DGF (7-9). It is believed that thymoglobulin 
has several pharmacologic properties, some of which can 
help to control the inflammation associated with ischemia 
reperfusion injury and thus reduce the risk of pathogenesis 
of DGF (10).
Objectives
The aim of this bi-center, historic cohort was to investigate 
DGF risk factors and to determine the association of 
intraoperative rATG with the risk of DGF in deceased 
donor kidney recipients at our centers.
Patients and Methods
Study population
In this study, we reviewed medical records of all consecutive 
first time deceased donor kidney transplant recipients 
who were on maintenance dialysis from December 2014 to 
January 2016 in 2 medical centers in Tehran. All patients 
in both centers received maintenance immunosuppressive 
treatment including tacrolimus (adjusted dose to reach 
whole blood trough level of 8-12 ng/mL), mycophenolate 
mofetil (500 mg TID), and prednisolone. In center one 
the standard protocol required rATG (1 mg/kg) infusion 
in the operating room prior to incision for 6-8 hours and 
repeated daily for 3-4 days. In center two intra-operative 
rATG was not administered and it was standard protocol 
to infuse thymoglobulin (1 mg/kg for 4-7 days) only to 
patients with urine output <75 mL/h within the first 48 
hours or failure of serum creatinine to decrease by 10% in 
the first 48 hours. All donors were standard heart beating, 
brain death donors. Unfortunately, due to retrospective 
nature of the study detailed information about donors 
and cold ischemic time was not available. We excluded 
patients with incomplete medical records and those with 
preemptive KT.
Definitions and variables
DGF was defined as the need for dialysis within the 
first week after KT. The cause of ESRD; duration of 
maintenance dialysis; the presence of DGF, intraoperative 
administration of thymoglobulin and total dose of rATG, 
operation duration, intraoperative transfusion, changes 
in systolic blood pressure after operation, duration of 
hospital stay, serum creatinine within the first 7 days 
after KT and at the time of hospital discharge, history of 
diabetes and hypertension, gender, weight, height and 
body mass index (BMI) of the patients were also recorded 
from patients’ medical reports.
Ethical issues
The research followed the tenets of the Declaration 
of Helsinki. Informed consent was taken from the 
patients. The study protocol was approved by local ethics 
committee of Tehran University of Medical Sciences (IR.
TUMS.VCR.REC.1395.71). This study was a part of the 
thesis by Neda Naderi, supported by Tehran University of 
Medical Sciences (#9411402003).
Statistical methods
Data were analyzed using SPSS (SPSS Inc., Chicago, IL, 
USA) version 16.0 software for descriptive statistics. 
Chi-square and student t test were used for categorical 
and continuous variables, respectively. We used STATA 
version 13.0 to calculate odds ratios and perform logistic 
regression analysis. A multivariate logistic regression 
model was used to investigate associations between DGF 
and putative risk factors. To evaluate the association 
between demographic and clinical variables with DGF 
we first used univariate regression analysis. Variables with 
a P value of less than 0.2 or those that to our previous 
knowledge could be associated with DGF were chosen. 
These variables were included in multivariate logistic 
regression. Variance inflation factor (VIF) was used 
to quantify the severity of multicollinearity and from 
variables with high collinearity one was included in the 
final regression model. Also, P value of less than 0.05 was 
considered statistically significant. 
Results
Patient population
Medical records of 234 deceased donor kidney recipients 
were reviewed. Seventy-one patients did not fulfill 
inclusion criteria (19 preemptive transplantation and 52 
incomplete medical records). A total of 163 patients were 
included in the study. The median age of the patients was 
44 years (11-73 years) and 63.8% (104) were male (Table 
1). Thirty-six (22.1%) patients experienced a more than 
20 mm Hg drop in systolic blood pressure and 27 (16.6%) 
received packed RBC during surgery. History of diabetes 
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mellitus was positive in 45 (27.6%) cases and the duration 
of dialysis before KT was 26.55 ± 25.93 months (1-156 
months). 
Eighty-nine patients from center one and seventy-four 
patients from center two were included in the study. Age, 
duration of dialysis prior to kidney transplant, duration 
of surgery, history of diabetes mellitus and BMI were 
significantly different in these two centers (Table 2). There 
was no statistically significant difference in other studied 
variables between the centers (Table 2).
Delayed graft function
The rate of DGF in kidney transplant recipients was 
27.0% (44/163). Unadjusted data showed that positive 
history for DM was observed in 50% (22/44) of DGF cases 
which was statistically significant (P < 0.001). Transfusion 
during operation and BMI >30 kg/m2 were significantly 
more common in DGF positive patients (22.9.5% 
versus 11.8%, P = 0.007; 15.9% versus 5.9%, P = 0.043, 
respectively). Mean serum creatinine concentration at the 
time of hospital discharge and length of hospital stay was 
significantly higher among patients with DGF compared 
to those without DGF (2.5 versus 1.4 mg/dL and 25 
versus 14 days, respectively). There was no statistically 
significant difference between age, sex, duration of 
dialysis, administration of rATG, BMI and history of 
hypertension between two groups (Table 3).
Our final regression model included age, gender, 
duration of dialysis, duration of transplant surgery, 
intraoperative administration of rATG, BMI, history of 
diabetes mellitus, more than 20 mm Hg drop in blood 
pressure after operation, and transfusion during surgery 
(Table 3). Intraoperative rATG administration was 
significantly associated with a lower rate of DGF (adjusted 
odds ratio [AOR], 0.33, 95% CI, 0.11-0.95). The need 
for intraoperative blood transfusion (AOR, 3.7, 95% CI, 
1.4-9.9) and presence of diabetes mellitus in transplant 
recipients (AOR, 3.7, 95% CI, 1.5-8.9) were significantly 
associated with higher risk of DGF. There was no 
statistically significant association between DGF and 
recipients’ age, gender, BMI or duration of pre-transplant 
dialysis (Table 3, Figure 1). The odds ratio for developing 
DGF was higher in patients with longer operation time 
but was not considered statistically significant (AOR, 
1.73, 95% CI, 0.98-3.04, P = 0.058). Age, gender, duration 
of dialysis before transplant, more than 20 mmHg drop 
in blood pressure after operation and BMI were not 
associated with increased risk of developing DGF.
Discussion
In this retrospective cohort study of 163 first time kidney 
transplant recipients we found that intraoperative rATG 
administration was associated with a decreased risk 
of DGF after adjustments for age, sex, BMI, duration 
of dialysis, history of diabetes mellitus, >20 mm Hg 
drop in systolic blood pressure, operation duration and 
intraoperative transfusion. Conversely, we identified that 
history of diabetes mellitus and need for intraoperative 
blood transfusion were associated with an increased risk 
of DGF that remained robust after adjustment for above 
variables.
The incidence of DGF has increased over time in 
concordance with the use of high-risk kidneys from 
expanded criteria donors and donation after cardiac death 
(11-13). Several modalities have been investigated in 
both deceased donors and recipients to attenuate the risk 
of DGF (14-16), such as using vasodilators, antioxidant 
agents, and different types of immunosuppressive 
induction (11). Currently, rATG, a lymphocyte-depleting 
polyclonal antibody, and basiliximab, an interleukin-2 
receptor monoclonal antibody, are the most commonly 
used biologic agents for immunosuppressive induction 
therapy in kidney transplant (17,18). Although the 
main purpose of the induction therapy is to lower the 
incidence of acute rejection, some reports surmised an 
additional role for rATG to reduce the rate of DGF by 
suppressing the alloimmunity and ischemia reperfusion 
injury (19, 20). There are several mechanisms by which 





Age (y) 43.80±13.48 (11-73)
Age of patient ≥65 years
No 157 (96.3%)
Yes 6 (3.7%)




Duration of dialysis before kidney 




Operation duration (h) 3.35±0.88 (1.5-6.0)
ATG received on operation day
No 74 (45.4%)
Yes 89 (54.6%)








Packed RBC transfusion during surgery
No 136 (83.4%)
Yes 27 (16.6%)
Hospitalization duration (days) 16.99±10.54 (7-90)
Serum creatinine at discharge (mg/dLl) 1.70±1.05 (0.6-11.3)
Data has been presented as number (percent) or mean± standard 
deviation (min-max).
BMI: Body mass index; DGF: Delayed graft function; RBC; Red blood 
cells.
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rATG may exert protective effects in the prevention of 
DGF. For instance, rATG therapy may be associated with 
amelioration of some of the mechanisms which underlie 
ischemia reperfusion injury (21, 22). In this regard, rATG 
therapy can exert its effects through blockade of adhesion 
molecules, reducing the surface expression of β2 integrin 
and importantly inducing T lymphocyte depletion. The 
presence of CD4 and CD8 T cells at the time of reperfusion 
may be associated with increased risk of reperfusion 
injury and DGF (19,23). The clinical impact of rATG 
has been evaluated in several studies which have shown 
that rATG as an induction therapy can be beneficial in 
deceased donor kidney transplant recipients with DGF 
(24-26). Goggins et al evaluated intraoperative and 
postoperative administration of rATG in deceased donor 
kidney transplant recipients in a prospective randomized 
study. They found that intraoperative thymoglobulin was 
associated with a significant decrease in DGF occurrence, 
better graft function within the first month post-
transplantation and shorter hospital stay (27). Recently, the 
effects of rATG as an induction immunosuppressive agent 
was studied in kidney transplant patients who received 
Table 2. Demographic and clinical characteristics of kidney recipients according to intraoperative administration of rATG (centers 1 and 2)
ATG received on operation day
Yes (n = 89, center 1) No (n = 74, center 2) P
Age 41.3±13.29 46.7±13.19 0.011
Duration of dialysis (mon) 31.3±29.29 20.9±19.95 0.010
Operation duration (h) 3.85±0.64 2.74±74 0.001
Serum creatinine at discharge 1.62±1.28 1.79±0.65 0.285
Hospitalization duration (days) 16.7±12.70 17.3±7.20 0.727
ATG dose (mg/kg) 4.96±1.26 5.28±1.91 (n=32)* <0.001
BMI 23.6±3.45 24.3±2.29 0.217
Gender (male) 53 (59.6%) 51 (68.9%) 0.215
History of Diabetes (positive) 19 (21.3%) 26 (35.1%) 0.050
>20 mm Hg drop in systolic BP 17 (19.1%) 19 (25.7%) 0.314
Transfusion during surgery 18 (20.2%) 5 (6.8%) 0.168
Age of patient equal or more than 65 1 (1.1%) 9 (12.2%) 0.057
BMI ≥30 4 (4.5%) 10 (13.5%) 0.041
History of hypertension 62 (69.7%) 53 (71.6%) 0.785
*rATG was administered after surgery in those patients with urine output <75 mL/h within the first 48 hours or failure of serum creatinine to decrease 
by 10% in the first 48 hours. 
Data has been presented as number (percent) or mean± standard deviation. 
BMI; Body mass index; DGF: Delayed graft function; RBC; Red blood cells
Table 3. Factors associated with delayed graft function in kidney recipient patients
Delayed graft function
Unadjusted OR (95% CI) Adjusted OR(95% CI)
No (119) Yes (44) P value
Age (y) 43.1±13.72 45.5±12.80 0.342 1.01 (0.99-1.04) 0.98 (0.95-1.02)
Sex (male) 77 (67.7%) 27 (61.4%) 0.693 1.15 (0.56-2.35) 1.22 (0.55-2.74)
Height (cm) 167.3±11.29 167.1±9.04 0.914
Weight (kg) 66.6±13.59 69.7±14.28 0.274
Duration of dialysis (mon) 27.3±27.06 24.4±22.73 0.527 0.99 (0.98-1.01) 0.99 (0.98-1.01)
Operation duration (h) 3.32±0.84 3.42±1.00 0.513 1.14 (0.77-1.69) 1.73 (0.98-3.04)
Serum creatinine at discharge (mg/dL) 1.40±0.39 2.5±1.68 <0.001
Hospitalization duration (days) 14.0±5.78 24.9±15.45 <0.001
ATG received on operation day 69 (57.0%) 20 (45.4%) 0.154 0.60 (0.30-1.21) 0.33 (0.11-0.95)
ATG total dose (mg/kg) 3.15±2.55 5.36±1.71 <0.001
BMI, kg/m2 23.7±3.76 24.7±4.08 0.145 1.07 (0.98-1.17) 1.06 (0.95-1.18)
History of diabetes mellitus (positive) 23 (19.3%) 22 (50%) <0.001 4.17 (1.98-8.80) 3.72 (1.55-8.95)
>20 mm Hg drop in Systolic BP 24 (20.2%) 12 (27.3%) 0.332 1.48 (0.67-3.30) 1.21 (0.49-3.02)
Transfusion during surgery 14 (11.8%) 13 (29.5%) 0.007 3.14 (1.34-7.39) 3.70 (1.38-9.94)
Age of patient ≥65 5 (4.2%) 1 (2.3%) 0.561
BMI ≥30 kg/m2 7 (5.9%) 7 (15.9%) 0.043
History of hypertension 81 (68.1%) 34 (77.3%) 0.252
Data has been presented as number (percent) or mean± standard deviation (min-max).
BMI; Body mass index, BP, blood pressure; ATG, antithymocyte globulin; OR, odds ratio. 
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the allograft from donors after brain death followed by 
circulatory death. The results showed that rATG induction 
therapy was associated with lower incidence of DGF 
(28). Furthermore, a recent investigation by Lee et al also 
revealed that even in low immunologic risk recipients, the 
incidence of biopsy-proven acute rejection was lower with 
thymoglobulin compared with basiliximab (29).
However, it should also be noted that there are also 
studies which compared the effects of rATG with 
newer antibody induction regimens (19,30,31). In a 
randomized controlled trial, Brennan et al indicated that 
rATG induction therapy was superior to basiliximab 
in preventing acute rejection episodes. However, there 
was no significant difference between the two groups 
regarding the incidence of DGF (30). A meta-analysis of 
randomized controlled trials was conducted by Zheng et 
al on efficacy and safety of rATG and alemtuzumab as 
induction therapy in kidney transplant recipients. The 
findings of this study demonstrated that there were no 
significant differences between alemtuzumab and rATG 
for biopsy-proven acute rejection, mortality, graft failure 
and DGF (31). In light of the discrepancy between the 
available studies on the role of rATG in the prevention 
of DGF, future studies will need to further the potential 
utility of this therapy for this condition.
Numerous factors in donors and recipients have 
been found to be associated with a greater risk of DGF 
development. In the recipients, male gender, older age, 
higher BMI, comorbid diabetes mellitus and longer pre-
transplant dialysis duration have been associated with 
DGF (6,32-34). In the present study, we did not find 
any significant association between DGF and recipients’ 
gender, age, BMI or pre-transplant dialysis duration. This 
discrepancy might be related to small sample size of our 
study.
The observed effect of pre-transplant transfusion on 
allograft survival has changed during recent decades. In 
earlier studies, it had been suggested that pre-transplant 
blood transfusion in deceased donor kidney transplant 
Figure 1. Adjusted odds ratios and confidence intervals for 
development of DGF in the final multivariate regression model. 
recipients, improved allograft survival due to increasing 
immune tolerance (35,36). In contrast, a systematic 
review of 180 studies in 2013 showed that pre-transplant 
blood transfusion was a major cause of allosensitization 
and consequently was correlated with enhanced risk of 
rejection and graft loss (37). A recent investigation by 
Mazzeffi et al examined the effect of intraoperative blood 
transfusion on renal allograft outcomes. The results of 
this study showed that intraoperative blood transfusion 
not only increased the risk of DGF but also increased the 
incidence of post-operative sepsis (38). In accordance 
with the study by Mazzeffi et al, we showed the role of 
intraoperative blood transfusion as a risk factor for DGF.
It has been shown that renal transplant recipients who 
are diabetic are at increased risk for development of DGF 
(32,39,40). During a retrospective study, Bzoma et al 
assessed the clinical consequences of recipients’ diabetes 
on the transplant outcomes of paired kidneys in diabetic 
and non-diabetic patients who received kidney grafts 
from the same donor. The result of the study showed that 
diabetic patients were exposed to more events of DGF 
(40). This finding is in agreement with our study that 
identified diabetes as a strong risk factor for DGF. Diabetes 
potentiates the severity of the ischemic reperfusion injury 
through chronic inflammation and oxidative stress. 
Additionally, hyperglycemia as a result of corticosteroid 
bolus at the time of ischemia reperfusion can accentuate 
oxidative stress and renal injury(41). In addition, 
perioperative cardiac events and hemodynamic instability 
predispose diabetic recipients to the development of DGF 
(42).
Conclusion
Our study showed that intraoperative rATG induction 
therapy was associated with decreased incidence of DGF. 
Additionally, the need for intraoperative transfusion and 
recipient diabetes were risk factors for DGF. These findings 
will need to be further evaluated in larger randomized 
clinical trials.
Study limitations
Several limitations of our study need to be mentioned. 
Firstly, the present study is retrospective in nature; 
therefore, a causal relationship cannot be inferred. 
Another limitation of the current study is the small sample 
size and the homogeneity of the patient population (all of 
the patients were from the Middle East) which limit its 
generalization to more heterogeneous patient populations. 
In addition, there were recipient, donor and graft related 
confounders that we could not evaluate their effects on 
DGF occurrence due to insufficient data collection.
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